TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03167086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empowered Relief (ER)
Description: Empowered Relief (ER): A single-session skills-based approximately 2-hr group intervention to treat chronic pain.~Format of intervention: Therapist-delivered PowerPoint presentation with experiential exercises. Experienced senior level psychologist and two (2) additional doctoral level psychologists will conduct the ER sessions.~Content of intervention: ER Participants have the 'ER Relaxation Resource' app (guided relaxation audiofile) loaded on their apple or android electronic device.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Format of intervention: 8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total). The group is run weekly for 8 consecutive classes. Each class is 2 hours with a midpoint break (16 hours total intervention time).~Content of intervention: The protocol and materials were developed with funding from NIH/NCCAM R01 AT006226 (Dan Cherkin, PI) \[1\& 2\], and include content from a pain-CBT program developed by Drs. Ehde, Dillworth, and Turner \[3\].~Participants receive a workbook with homework and a copy of The Pain Survival Guide: How to reclaim your life © 2005 by Turk \& Winter \[4\] for optional reading.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education (HE)
Description: Format of intervention: The HE class will be instructor taught and will involve a PowerPoint presentation and handouts. Two additional providers will be identified and trained to conduct the sessions. Selected instructors will have substantial health education experience.~Content of intervention: HE content will include basic information such as nutrition and interacting with the healthcare system; these relatively 'inert' topics are unlikely to impart any specific effects typically found with a true psychobehavioral intervention.
Study: NCT02292121

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intestinal permeability
Description: 5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intestinal permeability
Description: 5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
Study: NCT02634918

Intervention type: OTHER
Intervention: ultrasound
Description: ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III
Study: NCT01427491

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel® Ag
Description: Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mepilex® Border Ag
Description: Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
Study: NCT02300545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Study: NCT01726764

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: St John's Wort
Study: NCT02634918

Intervention type: OTHER
Intervention: ultrasound
Description: ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III

Intervention type: OTHER
Intervention: ultrasound
Description: ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III
Study: NCT01204658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK 2189242A (LD formulation 1)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK 2189242A (HD formulation 2)
Description: Intramuscular injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix
Description: Intramuscular injection
Study: NCT00758602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus, low dose
Description: Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8 to 10 ng/mL from Day 0 through Month 3; 0.05-0.08 mg/kg PO BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids
Description: According to center's practice
Study: NCT03848143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinum toxin A
Description: Each subject will receive 50 units (50 U) of BoNT-A constituted in 1 mL of saline solution injected intraorally to the painful area divided in at least 3 sites, 0.5 to 1.0 cm apart depending on the size of the painful area and following a checkerboard pattern.
Study: NCT03474029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine daily for 6 weeks
Description: 600 mg of Rifapentine (RPT) given once daily (o.d., omni die) for 6 weeks (6wP).
Study: NCT00758602

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: According to center's practice
Study: NCT03474029

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifapentine and Isoniazid weekly for 12 weeks
Description: Rifapentine (RPT) 900 mg and isoniazid (INH) 900 mg given once-weekly for 12 weeks (3HP).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RPT 900 mg once-weekly for persons weighing \> 50 kg. For persons weighing \< 50 kg, the following doses will be given: weight \> 25-32 kg - RPT 600 mg; weight \> 32-50 kg - RPT 750 mg; + INH 15 mg/kg (round up to nearest 50 or 100 mg; 900 mg max).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin and Isoniazid daily for 12 weeks
Description: Rifampin (RIF) 600 mg and Isoniazid (INH) 300 mg given once-daily for 12 weeks (3HR)\*.~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, give 10 mg/kg daily; round up to nearest 50 or 100 mg; + INH 5 mg/kg daily (rounded up to nearest 50 or 100 mg; 300 mg max).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin daily for 16 weeks
Description: Rifampin (RIF) 600 mg given once-daily for 16 weeks (4R).\*~\*Dose adjustments based on patient's weight will be made according to ATS/CDC/IDSA guidelines.~RIF 600 mg daily for persons weighing \> 50 kg. For persons weighing \< 50 kg, 10 mg/kg daily; round up to nearest 50 or 100 mg.
Study: NCT00385788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 800 mg/m\^2 IV over 30 minutes on Day -7 (1 day)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 33 mg/m\^2 IV over 30 minutes Day -5 to Day -2 (4 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 33 mg/m\^2 IV over 30 minutes Day -5 to Day -2 (4 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 IV over 30 minutes on Day -3 to Day -2 (2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 70 mg/m\^2 IV over 30 minutes on Day -3 to Day -2 (2 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: 2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antithymocyte Globulin
Description: 2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.~If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Infusion
Description: Infusion of stem cells on Day 0.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Infusion
Description: Infusion of stem cells on Day 0.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: 0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Description: Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
Study: NCT02283190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erwinase
Description: Six doses of Erwinase, given Monday-Wednesday-Friday for 2 weeks. Dosage levels to be used are: 20,000 IU/ m2 /day, 25,000 IU/ m2 /day, 30,000 IU/ m2 /day.
Study: NCT01629394

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Single dose of sugammadex 2 mg/kg ( ideal body weight )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Single dose of neostigmine 50 μg/kg ( ideal body weight )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Single dose of 2 mg/kg corrected body weight \[corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Single dose of sugammadex 2 mg/kg ( ideal body weight )

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Single dose of neostigmine 50 μg/kg corrected body weight \[corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Single dose of neostigmine 50μg/kg ( ideal body weight )
Study: NCT01726764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT04573972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Incentive
Description: Receiving half the monetary incentive conditional on meeting a step goal and half the monetary incentive conditional on walking together
Study: NCT00958802

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Description: PRP was extracted from total blood and TGF-b1 was used as indicator

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Chondrocyte culture with FBS medium
Description: Microtia chondrocyte culture with FBS medium only
Study: NCT04187209

Intervention type: DEVICE
Group type: OTHER
Intervention: Use of the Atalante exoskeleton
Description: A session includes a stand-up, walks over a distance of 10 meters, exercises with or without the assistance of the exoskeleton, U-turns and a sitting.
Study: NCT03092635

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC
Description: OPC is a derivative of grape seed extract
Study: NCT04372797

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diagnostic test
Description: A battery of oculomotor tests
Study: NCT03259932

Intervention type: OTHER
Group type: OTHER
Intervention: no physical activity
Description: no physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical activity
Description: Rehabilitation program will start 4 weeks after discharge from acute care (S4), for a duration of 8 weeks (3 sessions / week). Physical training will include aerobic exercises 30-60 minutes at 50-80% of HRmax, associated with muscle building exercises in circuit training (20 min), and balance and flexibility exercises.
Study: NCT04456348

Intervention type: OTHER
Intervention: there is no intervention
Description: There is no intervention

Intervention type: OTHER
Intervention: there is no intervention
Description: There is no intervention
Study: NCT04283825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological and physical rehabilitation based humanistic care
Description: This Psychological and physical rehabilitation based humanistic care regimen is generated from the experience of the National medical team members in Wuhan, from our hospital. In addition to the routine therapy, we will apply this comprehensive humanistic care regimen to the patients according to their condition. The patients will be stratified by the severity and receive different combinations of Psychological and physical rehabilitation activities.
Study: NCT03588845

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment Protocol
Description: Protocol treatment sites will be expected to see the patient within a pre-specified window of time. The doctors at that site will apply the treatment algorithm and will make decisions about response to treatment based on the algorithm and on specific patient answers to questionnaires. The treatment protocol will only be made available to IRBs, not to any site personnel before randomization. This was derived from a survey of rheumatologists in many countries and gastroenterologists, mostly in North America, who were asked multiple questions about how they would treat and follow up patients with suspected SIBO. Successful treatment is a response on GSS of no diarrhea plus a total GSS of \< 5.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care
Description: Physicians randomly assigned to standard of care will also be informed of their patients who met eligibility criteria. They will not be aware of the detailed treatment protocol but will be informed of which medications are in the protocol eg antibiotics, prokinetics etc. They will be free to contact the patients at their convenience and to treat them in any way they deem suitable, preferably using these medications but at doses and frequencies according to their own wishes.
Study: NCT04372797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diagnostic test
Description: A battery of oculomotor tests
Study: NCT01183780

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: 8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Study: NCT03384433

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: exosome
Description: allogenic mesenchymal stem cells derived exosome enriched by miR-124
Study: NCT01309217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Tactics Intervention
Description: At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals.
Study: NCT04573972

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Incentive
Description: Receiving the full monetary incentive conditional on meeting a step goal and not conditional on walking together
Study: NCT00378092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral risperidone
Description: Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
Study: NCT01183780

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan
Description: 180 milligrams/square meter (mg/m\^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 milligrams/square meter (mg/m\^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folinic Acid
Description: 400 mg/m\^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: 400 mg/m\^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: 400 mg/m\^2 bolus immediately followed by 2400 mg/m\^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 400 mg/m\^2 bolus immediately followed by 2400 mg/m\^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
Study: NCT01669148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tomosynthesis
Description: The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tomosynthesis
Description: The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: conventional (2D) imaging (standard mammography)
Study: NCT03329742

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low protein diet
Description: Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 10% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control protein diet
Description: Patients on this arm will receive a prescribed diet (including all food and recommendations for beverages) that contains 20% protein to begin eating 1 week prior to treatment with sipuleucel-T and throughout treatment (i.e. diet will last approximately 49 days).
Study: NCT00702806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Intra-abdominal injection of Org 36286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Intra-abdominal injection of Org 36286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286
Description: Intra-abdominal injection of Org 36286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puregon®
Description: Subcutaneous Puregon® 150 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puregon®
Description: Subcutaneous Puregon® 150 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Puregon®
Description: Subcutaneous Puregon® 150 IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Puregon®
Description: Subcutaneous Puregon® 150 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orgalutran®
Description: Subcutaneous Orgalutran® 0.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orgalutran®
Description: Subcutaneous Orgalutran® 0.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orgalutran®
Description: Subcutaneous Orgalutran® 0.25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Orgalutran®
Description: Subcutaneous Orgalutran® 0.25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnyl®
Description: Subcutaneous Pregnyl® 10,000 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnyl®
Description: Subcutaneous Pregnyl® 10,000 IU

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnyl®
Description: Subcutaneous Pregnyl® 10,000 IU

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregnyl®
Description: Subcutaneous Pregnyl® 10,000 IU